• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Lumos Pharma Inc. (Amendment)

    11/29/23 4:30:58 PM ET
    $LUMO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LUMO alert in real time by email
    SC 13D/A 1 d605126dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Lumos Pharma, Inc.

    (Name of Issuer)

    Common Stock, par value $0.01 per share

    (Title of Class of Securities)

    651511107

    (CUSIP Number)

    Robert Liptak

    Clarus Ventures, LLC

    314 Main Street, 15th Floor

    Cambridge, MA 02142

    (617) 949-2200

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    November 27, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 651511107

     

      1    

      NAMES OF REPORTING PERSONS

     

      Clarus Lifesciences III, L.P.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

      OO

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7    

      SOLE VOTING POWER

     

      385,683

         8  

      SHARED VOTING POWER

     

      0

         9  

      SOLE DISPOSITIVE POWER

     

      385,683

       10  

      SHARED DISPOSITIVE POWER

     

      0

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      385,683

    12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      4.9%

    14  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      PN

     

    2


    CUSIP No. 651511107

     

      1    

      NAMES OF REPORTING PERSONS

     

      Clarus Ventures III GP, L.P.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

      OO

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7    

      SOLE VOTING POWER

     

      385,683

         8  

      SHARED VOTING POWER

     

      0

         9  

      SOLE DISPOSITIVE POWER

     

      385,683

       10  

      SHARED DISPOSITIVE POWER

     

      0

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      385,683

    12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      4.9%

    14  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      PN

     

    3


    CUSIP No. 651511107

     

      1    

      NAMES OF REPORTING PERSONS

     

      Blackstone Clarus III L.L.C.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

      OO

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7    

      SOLE VOTING POWER

     

      385,683

         8  

      SHARED VOTING POWER

     

      0

         9  

      SOLE DISPOSITIVE POWER

     

      385,683

       10  

      SHARED DISPOSITIVE POWER

     

      0

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      385,683

    12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      4.9%

    14  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      OO

     

    4


    CUSIP No. 651511107

     

      1    

      NAMES OF REPORTING PERSONS

     

      Blackstone Holdings II L.P.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

      OO

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Quebec, Canada

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7    

      SOLE VOTING POWER

     

      385,683

         8  

      SHARED VOTING POWER

     

      0

         9  

      SOLE DISPOSITIVE POWER

     

      385,683

       10  

      SHARED DISPOSITIVE POWER

     

      0

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      385,683

    12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      4.9%

    14  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      PN

     

    5


    CUSIP No. 651511107

     

      1    

      NAMES OF REPORTING PERSONS

     

      Blackstone Holdings I/II GP L.L.C.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

      OO

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7    

      SOLE VOTING POWER

     

      385,683

         8  

      SHARED VOTING POWER

     

      0

         9  

      SOLE DISPOSITIVE POWER

     

      385,683

       10  

      SHARED DISPOSITIVE POWER

     

      0

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      385,683

    12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      4.9%

    14  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      OO

     

    6


    CUSIP No. 651511107

     

      1    

      NAMES OF REPORTING PERSONS

     

      Blackstone Inc.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

      OO

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7    

      SOLE VOTING POWER

     

      385,683

         8  

      SHARED VOTING POWER

     

      0

         9  

      SOLE DISPOSITIVE POWER

     

      385,683

       10  

      SHARED DISPOSITIVE POWER

     

      0

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      385,683

    12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      4.9%

    14  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      CO

     

    7


    CUSIP No. 651511107

     

      1    

      NAMES OF REPORTING PERSONS

     

      Blackstone Group Management L.L.C.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

      OO

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7    

      SOLE VOTING POWER

     

      385,683

         8  

      SHARED VOTING POWER

     

      0

         9  

      SOLE DISPOSITIVE POWER

     

      385,683

       10  

      SHARED DISPOSITIVE POWER

     

      0

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      385,683

    12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      4.9%

    14  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      OO

     

    8


    CUSIP No. 651511107

     

      1    

      NAMES OF REPORTING PERSONS

     

      Stephen A. Schwarzman

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

      OO

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7    

      SOLE VOTING POWER

     

      385,683

         8  

      SHARED VOTING POWER

     

      0

         9  

      SOLE DISPOSITIVE POWER

     

      385,683

       10  

      SHARED DISPOSITIVE POWER

     

      0

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      385,683

    12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      4.9%

    14  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      IN

     

    9


    Item 1.

    Security and Issuer

    This Amendment No. 1 to Schedule 13D (“Amendment No. 1”) amends and supplements the statement on Schedule 13D originally filed with the United States Securities and Exchange Commission (the “SEC”) on March 30, 2020 (as amended, the “Schedule 13D”) related to the common stock, par value $0.01 per share (the “Common Stock”) of Lumos Pharma, Inc. (f/k/a NewLink Genetics Corporation), a Delaware corporation (the “Issuer”). The address of the principal executive office of the Issuer is 4200 Marathon Blvd #200, Austin, Texas 78756.

    The Items below amend the information disclosed under the corresponding Items of the Schedule 13D as described below. Except as specifically provided herein, this Amendment No. 1 does not modify any of the information previously reported in the Schedule 13D. Capitalized terms used but not defined herein shall have the meanings attributed to them in the Schedule 13D.

     

    Item 2.

    Identity and Background

    Items 2 (a)-(c) of the Schedule 13D are hereby supplemented as follows:

    The Blackstone Group Inc. is now known as Blackstone Inc. Blackstone Inc. is a Delaware corporation. Information regarding each director and executive officer of Blackstone Inc. is set forth on the updated Schedule I attached hereto. The principal business of Blackstone Group Management L.L.C. is performing the functions of, and serving as, the sole holder of the Series II preferred stock of Blackstone Inc.

     

    Item 5.

    Interest in Securities of the Issuer

    Items 5 (a)-(c) and (e) of the Schedule 13D are hereby amended and restated as follows:

    (a) and (b) Calculations of the percentage of beneficial ownership in this Schedule 13D are based on 7,914,582 shares of Common Stock outstanding as of November 2, 2023, as set forth in the Issuer’s Quarterly Report on Form 10-Q filed by the Issuer on November 7, 2023

    The aggregate number and percentage of the Common Stock beneficially owned by each Reporting Person and, for each Reporting Person, the number of shares as to which there is sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition are set forth on rows 7 through 11 and row 13 of the cover pages of this Schedule 13D and are incorporated herein by reference.

    As of the date hereof, Clarus Lifesciences III, L.P. (the “Fund”) directly holds 385,683 shares of Common Stock.

    Clarus Ventures III GP, L.P. is the general partner of the Fund. Blackstone Clarus III L.L.C. is the general partner of Clarus Ventures III GP, L.P. The sole member of Blackstone Clarus III L.L.C. is Blackstone Holdings II L.P. The general partner of Blackstone Holdings II L.P. is Blackstone Holdings I/II GP L.L.C. The sole member of Blackstone Holdings I/II GP L.L.C. is Blackstone Inc. The sole holder of the Series II preferred stock of Blackstone Inc. is Blackstone Group Management L.L.C. Blackstone Group Management L.L.C. is wholly-owned by Blackstone’s senior managing directors and controlled by its founder, Stephen A. Schwarzman.

    Neither the filing of this Schedule 13D nor any of its contents shall be deemed to constitute an admission that any Reporting Person is the beneficial owner of the Common Stock referred to herein for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, or for any other purpose and each of the Reporting Persons expressly disclaims beneficial ownership of such shares of Common Stock.

    (c) Except as set forth below, which presents information as of 4:30 p.m. Eastern on November 27, 2023, none of the Reporting Persons has effected any transaction in Common Stock during the past 60 days.

    The following shares of Common Stock held by the Fund were sold in multiple open market sale transactions as described below.

     

    10


    Date

       Number of Shares
    Sold
         Weighted Average
    Price Per Share
         Price Range per
    Share Low
         Price Range per
    Share High
     

    11/9/2023

         12,085      $ 3.794801      $ 3.765000      $ 3.815000  

    11/14/2023

         17,948      $ 3.110386      $ 3.100000      $ 3.200000  

    11/15/2023

         6,499      $ 3.101933      $ 3.100000      $ 3.137500  

    11/17/2023

         200      $ 3.100000        N/A        N/A  

    11/20/2023

         500      $ 3.100000        N/A        N/A  

    11/21/2023

         13,642      $ 3.100654      $ 3.100000      $ 3.120000  

    11/22/2023

         211      $ 3.100000        N/A        N/A  

    11/24/2023

         10,206      $ 3.100127      $ 3.100000      $ 3.135000  

    11/27/2023

         21,171      $ 3.124428      $ 3.100000      $ 3.200000  

    The Reporting Persons undertake to provide, upon request of the staff of the Securities and Exchange Commission, full information regarding the number of shares of Common Stock sold at each separate price within the price ranges set forth on the table above.

    (e) Following the sale of securities described herein, the Reporting Persons no longer beneficially own more than 5% of the outstanding Common Stock.

     

    11


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: November 29, 2023

     

    CLARUS LIFESCIENCES III, L.P.

    By: Clarus Ventures III GP, L.P., its general partner

    By: Blackstone Clarus III, LLC, its general partner

    By:   /s/ Omar Rehman

    Name: Omar Rehman

    Title: Authorized Signatory

    CLARUS VENTURES III GP, L.P.

    By: Blackstone Clarus III, LLC, its general partner

    By:   /s/ Omar Rehman

    Name: Omar Rehman

    Title: Authorized Signatory

    BLACKSTONE CLARUS III L.L.C.

    By:   /s/ Omar Rehman

    Name: Omar Rehman

    Title: Authorized Signatory

    BLACKSTONE HOLDINGS II L.P.

    By: Blackstone Holdings I/II GP L.L.C., its general partner

    By:   /s/ Tabea Hsi

    Name: Tabea Hsi

    Title: Senior Managing Director

    BLACKSTONE HOLDINGS I/II GP L.L.C.

    By: Blackstone Inc., its sole member

    By:   /s/ Tabea Hsi

    Name: Tabea Hsi

    Title: Senior Managing Director

    BLACKSTONE INC.

    By:   /s/ Tabea Hsi

    Name: Tabea Hsi

    Title: Senior Managing Director

    BLACKSTONE GROUP MANAGEMENT L.L.C.
    By:   /s/ Tabea Hsi

    Name: Tabea Hsi

    Title: Senior Managing Director


    /s/ Stephen A. Schwarzman

    Stephen A. Schwarzman


    SCHEDULE I

    Executive Officers and Directors of Blackstone Inc.

    The name and principal occupation of each director and executive officer of Blackstone Inc. are set forth below. The address for each person listed below is c/o Blackstone Inc., 345 Park Avenue, New York, New York 10154. All executive officers and directors listed are United States citizens other than The Right Honourable Brian Mulroney, who is a citizen of Canada.

     

    OFFICERS:   

    Name

      

    Present Principal Occupation or Employment

    Stephen A. Schwarzman    Founder, Chairman and Chief Executive Officer of Blackstone Inc.
    Jonathan D. Gray    President, Chief Operating Officer of Blackstone Inc.
    Michael S. Chae    Chief Financial Officer of Blackstone Inc.
    John G. Finley    Chief Legal Officer of Blackstone Inc.
    DIRECTORS:   

    Name

      

    Present Principal Occupation or Employment

    Stephen A. Schwarzman    Founder, Chairman and Chief Executive Officer of Blackstone Inc.
    Jonathan D. Gray    President, Chief Operating Officer of Blackstone Inc.
    Kelly A. Ayotte    Former United States Senator from New Hampshire
    Joseph P. Baratta    Global Head of Private Equity at Blackstone Inc.
    James W. Breyer    Founder and Chief Executive Officer of Breyer Capital
    Reginald J. Brown    Partner for the law firm, Kirkland & Ellis
    Rochelle B. Lazarus    Chairman Emeritus & Former Chief Executive Officer, Ogilvy & Mather Worldwide
    The Right Honourable Brian Mulroney    Senior Partner for the Montreal law firm, Norton Rose Fulbright Canada LLP
    William G. Parrett    Retired CEO of Deloitte Touche Tohmatsu and retired Senior Partner of Deloitte (USA)
    Ruth Porat    President and Chief Investment Officer; Chief Financial Officer of Alphabet Inc. and Google Inc.
    Get the next $LUMO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LUMO

    DatePrice TargetRatingAnalyst
    11/4/2021$27.00 → $28.00Buy
    HC Wainwright & Co.
    7/21/2021$34.00 → $27.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $LUMO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Lumos Pharma Inc.

      SC 13G - LUMOS PHARMA, INC. (0001126234) (Subject)

      11/12/24 6:27:22 PM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Lumos Pharma Inc. (Amendment)

      SC 13G/A - LUMOS PHARMA, INC. (0001126234) (Subject)

      2/9/24 7:14:19 PM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Lumos Pharma Inc.

      SC 13G - LUMOS PHARMA, INC. (0001126234) (Subject)

      2/6/24 9:57:23 AM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LUMO
    SEC Filings

    See more
    • SEC Form 15-12G filed by Lumos Pharma Inc.

      15-12G - LUMOS PHARMA, INC. (0001126234) (Filer)

      12/23/24 8:00:07 AM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form AW filed by Lumos Pharma Inc.

      AW - LUMOS PHARMA, INC. (0001126234) (Filer)

      12/13/24 8:10:29 AM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Lumos Pharma Inc.

      EFFECT - LUMOS PHARMA, INC. (0001126234) (Filer)

      12/13/24 12:15:10 AM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LUMO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors

      Aviceda Therapeutics ("Aviceda"), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment car

      4/9/25 7:00:00 AM ET
      $ANNX
      $LUMO
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures' Acquisition of Lumos Pharma

      AUSTIN, Texas and GREENWICH, Conn., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO) ("Lumos Pharma" or the "Company"), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, and Double Point Ventures LLC ("DPV") today announced the successful completion of the previously announced tender offer for Lumos Pharma's shares at a purchase price of (i) $4.25 per share in cash at closing, without interest and less applicable tax withholding and (ii) one contingent value right ("CVR") for each share of common stock outstanding, representing the future right to receive additional contingent cash payments upon the achievement of certain milestone even

      12/12/24 8:47:38 AM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM-201 to 24 Months in PGHD and Correlation of Growth to LUM-201's Unique Pulsatile Mechanism of Action

      AUSTIN, Texas, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that new analyses of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials were presented orally at the 62nd Annual European Society for Paediatric Endocrinology Meeting, or ESPE 2024, held November 16-18, 2024 in Liverpool, UK. "The new analyses and updated data from our Phase 2 OraGrowtH210 and OraGrowtH212 Trials presented at ESPE this week demonstrate sustained growth on LUM-201 in moderate Pediatric Growth Hormone Deficiency (PGHD) to 24 months, as well as the correlation of LUM-201's pulsatile

      11/21/24 9:00:00 AM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LUMO
    Financials

    Live finance-specific insights

    See more
    • Lumos Pharma Reports Second Quarter 2024 Financial Results and Provides Clinical Development Update

      Following Positive End of Phase 2 Meeting with FDA, Company Continues to Advance Plans for Phase 3 Placebo-Controlled Trial of LUM-201 in Moderate Pediatric Growth Hormone Deficiency Expects to Initiate Phase 3 Trial in Q2 2025 Company to Host Conference Call Today at 4:30PM ET AUSTIN, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced financial results for the quarter ended June 30, 2024 and provided a clinical programs update. "Following our very positive and productive End of Phase 2 Meeting with the FDA, we've made substantial progress finalizing our proposa

      8/1/24 4:05:00 PM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lumos Pharma to Report Second Quarter 2024 Financial Results and Provide Clinical Update on August 1, 2024

      AUSTIN, Texas, July 23, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, announced it will report second quarter 2024 financial results after the market close on Thursday, August 1, 2024. The company will host a conference call and webcast at 4:30pm ET that day to discuss these financial results and provide an update on clinical and corporate activities. A question-and-answer session will follow the prepared remarks. Conference Call and Webcast Details Date: Thursday, August 1, 2024Time: 4:30pm ETDial-in: 1- 866-652-5200 or 1- 412-317-6060 (International)Conference ID: 10191274 Dial-in registratio

      7/23/24 4:05:00 PM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results

      Outcome from End-of-Phase 2 Meeting Supportive of a Placebo-Controlled Phase 3 Trial Updated 12 and 24-Month Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials Continue to Show Oral LUM-201 Achieves Significant Increase in Growth from Baseline, Durable Effect to 24 Months Company to Host Conference Call May 15, 2024, at 8:30AM ET AUSTIN, Texas, May 14, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, today announced the outcome from its End-of-Phase 2 meeting with the FDA, provided a clinical programs update, and reported financial results for the quarter ended March 31

      5/14/24 4:15:00 PM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LUMO
    Leadership Updates

    Live Leadership Updates

    See more
    • Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors

      Aviceda Therapeutics ("Aviceda"), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment car

      4/9/25 7:00:00 AM ET
      $ANNX
      $LUMO
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lumos Pharma Appoints Pediatric Endocrinologist Experienced in Clinical Research and Pharmaceutical Development, Mark Bach, M.D., Ph.D., to Clinical Scientific Advisory Board

      AUSTIN, Texas, July 26, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that Mark Bach, M.D., Ph.D., accepted his appointment to the Company's Clinical Scientific Advisory Board (CSAB) effective July 15, 2021. Dr. Bach joins the Company's accomplished advisory board comprised of noted pediatric endocrinologists, Peter Clayton, M.D., Ph.D.; Reiko Horikawa, M.D., Ph.D.; George Werther, M.D., Ph.D.; and Chairman, Ron Rosenfeld, M.D. Dr. Bach is currently the Chief Medical Officer for ShouTi Inc., having recently joined from Ascendis Pharma where he served as Senior Vice President, End

      7/26/21 4:18:40 PM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lumos Pharma Announces Retirement of Carl Langren and Names Lori Lawley Chief Financial Officer in Planned Succession

      AUSTIN, Texas, April 20, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced several changes to its executive team as the Company celebrates one year since the close of its merger. After a distinguished 40-year career as an accountant and financial executive, including over 15 successful years with the Company and its predecessor, Chief Financial Officer Carl Langren has announced his plans to retire effective as of July 4, 2021. Mr. Langren has served as CFO of the Company since November 2018. After his departure, Mr. Langren will continue to serve as a consultant to Lumos Pharma for a

      4/20/21 4:05:00 PM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LUMO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Hawkins Richard J returned 757,562 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - LUMOS PHARMA, INC. (0001126234) (Issuer)

      12/13/24 9:32:39 PM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Zoth Lota S. returned 2,187 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - LUMOS PHARMA, INC. (0001126234) (Issuer)

      12/13/24 9:32:27 PM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Scientific Officer Mckew John C. returned 13,153 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - LUMOS PHARMA, INC. (0001126234) (Issuer)

      12/13/24 9:32:17 PM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LUMO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Lumos Pharma with a new price target

      HC Wainwright & Co. reiterated coverage of Lumos Pharma with a rating of Buy and set a new price target of $28.00 from $27.00 previously

      11/4/21 6:27:17 AM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Lumos Pharma with a new price target

      HC Wainwright & Co. reiterated coverage of Lumos Pharma with a rating of Buy and set a new price target of $27.00 from $34.00 previously

      7/21/21 11:37:35 AM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lumos Pharma upgraded by Stifel with a new price target

      Stifel upgraded Lumos Pharma from Hold to Buy and set a new price target of $24.00 from $4.00 previously

      3/11/21 8:10:40 AM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care